Bpifrance

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Mycophyto is a French company founded in 2016, co-created by microbiologist Justine Lipuma and Senior Research Engineer Christine Poncet-Doise. Based in Mougins, the company focuses on developing biological solutions aimed at revitalizing soil and enhancing plant growth. Mycophyto specializes in analyzing soil to identify indigenous fungi and pathogens beneficial for plant development. By isolating, multiplying, and inoculating mycorrhizae, the company provides customized products and support services for new agricultural systems. This innovative approach allows plant researchers to cultivate crops and herbs using natural soil microorganisms, minimizing reliance on chemical fertilizers and promoting sustainable agricultural practices.

Apmonia Therapeutics is focused on developing next-generation peptide-based therapies aimed at improving treatment options for various types of cancer, including glioblastoma, ovarian, colorectal, and pancreatic cancers. The company concentrates on targeting the tumor microenvironment, which plays a crucial role in cancer progression. By creating innovative drugs, Apmonia Therapeutics seeks to enhance therapeutic strategies for solid tumors and provide new perspectives in cancer treatment. Their approach includes the development of personalized immunotherapy solutions that utilize proprietary therapeutic peptides, ultimately aiming to improve the quality of life for patients battling cancer and assisting researchers in their efforts to advance cancer therapies.

Operator of a biotechnology company intended to develop drugs targeting specifically a new class of proteins involved in the resolution of inflammation. The company develops treatments based on monoclonal antibodies by treating human mucosal inflammatory diseases by inhibiting a target that could be implied in the early inflammatory process and the recruitment of innate immunity cells, enabling healthcare providers to cure their patients.

Operator of a regenerative medicine company intended to develop breast regeneration alternatives by 3D bioprinting. The company develops a bioprosthesis for breast reconstruction, enabling women to regain their self-confidence through natural products and get long-lasting and aesthetic results after the surgery.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.

Phagos Biotech is a biotechnology company focused on combating antibiotic resistance through innovative bacteriophage solutions. The company develops customizable treatments designed to replace traditional antibiotics in animal farming, specifically targeting bacterial infections in seafood and livestock. By utilizing bacteriophages, which are natural predators of bacteria, Phagos aims to provide an efficient and sustainable alternative for health professionals dealing with incurable and life-threatening infections. This approach addresses the urgent need for effective treatments in the face of rising antibiotic resistance, contributing to safer agricultural practices and improved animal health.

Developer of a plant-based food technology designed to reduce meat consumption. The company's technology offers plant-based whole-cuts that contain plant proteins, enabling consumers to have alternatives that mimic the taste, texture, and smell of meat.

Developer of a plant-based food technology designed to reduce meat consumption. The company's technology offers plant-based whole-cuts that contain plant proteins, enabling consumers to have alternatives that mimic the taste, texture, and smell of meat.

Brenus Pharma is focused on developing cell-based immunotherapies aimed at treating solid tumors. The company utilizes an allogeneic platform to create anti-cancer cell vaccines, which leverage the patient's immune system to combat cancer and reduce the risk of treatment resistance. Their approach emphasizes generating multiple candidate therapies efficiently, allowing for cost-effective scaling and integration with existing treatment standards. With a strong intellectual property portfolio and a team of experienced professionals, including renowned oncologists, Brenus Pharma seeks to educate the immune system to recognize and respond to tumor-associated and tumor-specific antigens, enhancing the effectiveness of chemotherapy and radiotherapy in cancer care.

LISAqua operates a sustainable aquaculture farm focused on breeding prawns using an innovative process that avoids antibiotics and pollution. The company's farming methodology incorporates advanced predictive modeling technology to monitor and anticipate changes in pond water conditions. By employing the perm aquaculture method, which integrates complementary species to create a closed marine ecosystem, LISAqua aims to provide responsibly sourced seafood to consumers and communities. This approach not only enhances environmental sustainability but also promotes healthy seafood production.

CarbonWorks specializes in the development of algae photobioreactors that utilize microalgae to capture and convert carbon dioxide. The company's technology industrializes microalgal photosynthesis, enabling the transformation of carbon emissions from various manufacturers into biomass. This biomass can be used in agricultural biocontrol products, as well as in human and animal food markets. By focusing on the large-scale production of safe bioproducts, CarbonWorks aims to help industries reduce their carbon footprints and promote sustainability.

Cell-Easy SAS operates as a stem cell contract development and manufacturing organization (CDMO) that provides ready-to-inject adipose derived allogeneic stem cells for preclinical and clinical development projects. The company’s allogeneic production process allows using the biological material of a healthy donor to help thousands of patients. The company was incorporated in 2017 and is based in Toulouse, France.

Elicit Plant is an agro-biotech company focused on enhancing the water resistance of crops and developing innovative phytosterol-based solutions. The company aims to facilitate the ecological transition in agriculture by addressing global challenges posed by climate change, particularly its impact on major crops. Elicit Plant utilizes proprietary technology that leverages phytosterols to improve plant stress resistance and activate natural defenses. Extensive field trials conducted across three continents have shown that these biosolutions are a viable option for farmers, offering consistent and significant returns on investment.

Developer a biotechnology platform intended to improve the quality of life of patients. The company's platform specializes in developing an alternate method for the depletion of senescent cells in age-related pathologies using immunotherapy with cancer therapy and senescence, enabling patients to have proper health and treatment.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.

Depixus SAS is a biotechnology company based in Paris, France, focused on the development of advanced technology for extracting genetic and epigenetic information from single molecules of DNA and RNA. Its main product, SIMDEQ™ (SIngle-molecule Magnetic DEtection and Quantification), enables fast, accurate, and cost-effective analysis of genomes and epigenetic modifications. Initially developed at École Normale Supérieure by prominent researchers, SIMDEQ™ allows for the identification, counting, full sequencing, and epityping of millions of individual DNA molecules with high precision. The technology has broad applications in the life sciences and medical fields, facilitating real-time analysis of biomolecular interactions and supporting researchers in uncovering new biological pathways, understanding disease mechanisms, and advancing precision medicine. With substantial validation completed, Depixus is moving towards platform optimization and commercialization to enhance its offerings in these critical areas.

Meiogenix SAS is a biotechnology company based in Paris, France, that specializes in developing breeding and genomic technologies aimed at unlocking the unexplored genetic diversity of organisms. Established in 2010, Meiogenix offers innovative solutions such as SpiX technology, which enhances homologous recombination in specific regions of the genome, and PhoeniX, a non-genetically modified method that facilitates meiotic recombination in hybrid diploid or polyploid yeast cells. These advancements enable the company to support the development of new products that address pressing global food and industrial challenges, expanding natural biodiversity through natural breeding techniques.

Spartha Medical is a medical technology company focused on developing eco-friendly, invisible coatings designed for medical devices and consumer products to mitigate microbial and inflammatory risks. Utilizing natural biopolymers, the company’s innovative coatings possess antibacterial, antiviral, and anti-inflammatory properties, providing an effective solution for infection control. The technology relies on a patented method of supramolecular assembly, enabling precise control over the properties of the coatings based on specific applications. This approach allows for the creation of multifunctional and easy-to-apply surface treatments that help healthcare institutions maintain disease-free environments on medical devices.

MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.

Lysogene S.A. is a biotechnology company based in Neuilly-sur-Seine, France, focused on the research and clinical development of gene therapy for neurodegenerative disorders. Founded in 2009, the company is advancing several clinical programs, including LYS-SAF302, currently in Phase II/III trials for the treatment of mucopolysaccharidosis type IIIA, and LYS-GM101, which is in Phase I/II trials for GM1 gangliosidosis. Lysogene is also engaged in a collaborative research effort with the Weizmann Institute of Science to develop a novel AAV gene therapy approach targeting neuronopathic Gaucher disease, Parkinson's disease, and other conditions. The company aims to enhance the health outcomes of patients suffering from life-threatening, incurable disorders by utilizing AAV vectors that effectively deliver genetic material to the central nervous system.

Egle Therapeutics SAS, a biotechnology company, develops immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases. It develops Treg modulating drug pipeline, which includes computationally designed resurfaced IL-2 proprietary variants to engage or dis-engage Tregs. The company was founded in 2020 and is based in Paris, France.

Operator of a food biotech firm dedicated to the development of the insect-rearing industry intended to feed and preserve the world. The company specializes in rearing and transforming insects into organic fertilizers and proteins for animal nutrition, especially for the aquaculture and pet food markets, enabling the agri-food industry to feed the world sustainably and preserve it through bioconversion.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Provepharm life Solutions is a truly unique life sciences research and pharma company, dedicated to a new era of discovery. We are a new global leader in human health with new Life Solutions, manufactured and developed from our core technology: Molecule Vitalization. As PROVEPHARM LIFE SOLUTIONS, we are building a new powerhouse for Research Services, Manufacturing Services and Speciality Care.

LISAqua operates a sustainable aquaculture farm focused on breeding prawns using an innovative process that avoids antibiotics and pollution. The company's farming methodology incorporates advanced predictive modeling technology to monitor and anticipate changes in pond water conditions. By employing the perm aquaculture method, which integrates complementary species to create a closed marine ecosystem, LISAqua aims to provide responsibly sourced seafood to consumers and communities. This approach not only enhances environmental sustainability but also promotes healthy seafood production.

PEP-Therapy SAS is a biotechnology company based in Evry, France, founded in 2014. The company specializes in the development of cell penetrating and interfering peptides (CP and IP) aimed at delivering targeted therapies for severe diseases, particularly cancer. One of its key products is DPT-PEP1, a peptide designed to inhibit Caspase-9/PP2A protein interactions, effectively triggering apoptosis in cancer cells while preserving the functionality of healthy cells and other signaling pathways. By focusing on the intracellular delivery of these peptides, PEP-Therapy aims to address critical pathological mechanisms, offering a promising approach to cancer treatment.

Gourmey is a pioneering company based in Paris, France, that specializes in the development and production of ethical foie gras derived from duck cells. Founded in 2019, it is recognized as France's first cultivated meat company, aiming to revolutionize the meat industry by offering a humane and sustainable alternative to traditional practices. Gourmey's innovative process involves cultivating duck cells in a controlled laboratory environment, where they are provided with optimal conditions, including temperature, nutrients, and space to grow. This method allows the company to produce foie gras without the need for force-feeding or slaughter, aligning with its commitment to health, environmental sustainability, and animal welfare.

Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.

METabolic EXplorer S.A., an industrial biochemical company, engages in the development and industrial of industrial fermentation processes as alternatives to petrochemical processes worldwide. Its functional ingredients of natural origin are used in the formulation of cosmetics and nutrition-animal health products and as intermediates for the synthesis of biomaterials. The company was founded in 1999 and is based in Saint-Beauzire, France.

Manufacturer of nitrogen products and fertilizers intended to restore fertility and natural health of all soils. The company engages in the production of a range of crop protection products including soil conditioners, microbial concentrates, natural seed protection products, and more, enabling farmers to improve seed and seedling resistance to seedling diseases and pest attacks.

Developer of a plant-based food technology designed to reduce meat consumption. The company's technology offers plant-based whole-cuts that contain plant proteins, enabling consumers to have alternatives that mimic the taste, texture, and smell of meat.

Aqemia is a Paris-based start-up founded in 2019 that specializes in in silico drug discovery. The company aims to accelerate the development of innovative therapeutic molecules by utilizing advanced generative AI and unique Statistical Mechanics algorithms. Aqemia's platform is designed to predict the affinity between drug candidates and their therapeutic targets with a speed and accuracy that is significantly superior to traditional methods. This capability allows researchers to efficiently guide the generation of compounds that have a higher likelihood of success in drug development. As a spin-off from École Normale Supérieure, Aqemia leverages eight years of research, drawing on expertise from fields such as Medicinal Chemistry, Statistical Mechanics, and Artificial Intelligence. The company's mission is to enhance the drug discovery process and improve the chances of finding effective treatments for various diseases.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

Kyanos specializes in the production of microalgae-based food products, focusing on sustainability and environmental health. The company employs an innovative process for cultivating high-value polysaccharides and pigments using high-output micro-algae in vertical photo-reactors. This patented technology significantly enhances productivity while minimizing environmental impact. Kyanos aims to provide consumers with sustainable and contaminant-free food options, thereby contributing to a healthier planet and promoting eco-friendly dietary choices.

Olgram is a biotechnology company focused on developing innovative solutions to combat chronic bacterial infections and address immune deficiencies resulting from conditions like traumatic brain injury and concussions. The company specializes in marine molecules, particularly those derived from algae, to create new products that target dormant bacteria responsible for infectious relapses. Through its research, Olgram is pioneering a new class of anti-infectives aimed at effectively eliminating persistent bacterial strains. Its dual approach not only seeks to treat stubborn bacterial infections but also aims to enhance immune responses, thereby contributing to more effective treatments for patients suffering from various infectious diseases.

PILI Inc. researches and manufactures bio-fabricated colors by using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting colors. PILI Inc. produces renewable dyes and pigments. The company was founded in 2012 and is based in Paris, France.

Step Pharma, founded in 2014 and based in Paris, France, is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. A spin-off of the Imagine Institute, Step Pharma emerged from research led by Professor Alain Fischer on genetic immunodeficiencies. The company collaborates with Sygnature Discovery, a prominent drug discovery services provider, and Kurma Partners, an investor focused on healthcare and biotechnology in Europe. Its proprietary therapeutics utilize a unique class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and improving therapeutic outcomes for patients with autoimmune disorders.

Seekyo SAS is a biotechnology company based in Poitiers, France, established in 2018. The company specializes in developing innovative treatment options for cancer patients, focusing on the creation of smart molecular systems. These systems are designed to transport potent anticancer agents selectively, targeting the microenvironment of solid tumors while minimizing harm to healthy tissues. Seekyo's approach utilizes advanced technologies such as antibody drug conjugates and small molecule drug conjugates, which specifically recognize cancer cell surface markers and tumor microenvironment characteristics. This allows for the controlled release of therapeutic agents directly at the tumor site, enhancing treatment efficacy and reducing adverse effects. By prioritizing the safety and effectiveness of chemotherapy, Seekyo aims to improve the overall treatment experience for cancer patients.

OncoDiag is a French biotechnology company located in Normandy, dedicated to creating non-invasive diagnostic tests aimed at the early detection of cancers. Its flagship product, the Urotest, is a urine test approved for the diagnosis and monitoring of bladder cancer. In addition to the Urotest, OncoDiag is developing Colodiag, a test focused on the early identification of colorectal cancer, and other diagnostic tools, including a tissue-based test for predicting non-evolutive localized prostate cancer. Through its innovative testing kits, OncoDiag aims to enhance cancer diagnostics, allowing healthcare professionals to provide timely and effective patient care.

CVasThera is a biopharmaceutical company focused on creating innovative therapies for cardiovascular and bowel diseases, particularly targeting conditions such as Crohn's disease. The company has secured an exclusive global license for two patents that emerged from four years of collaborative research involving the French National Institute of Health and Medical Research and the École des Mines d’Albi. By leveraging this research, CVasThera aims to provide effective treatment options for patients experiencing moderate to severe flare-ups, especially those reliant on corticosteroids.

Operator of a biotechnological therapeutic platform intended to provide financial assistance and operational excellence to early-stage projects. The company's platform identifies, selects, and incubates early-stage biotechnology projects that focus on selected therapeutic areas such as rare diseases, neurological disorders, oncology, and immunology, enabling startups to further develop their medicinal and drug research process.

Omini is a company that specializes in the development of portable and multipurpose bio-sensing devices for blood tests, catering primarily to general practitioners. Established in 2019 and headquartered in Saint Mandé, France, Omini addresses a critical need in medical decision-making, as 70% of such decisions rely on clinical chemistry and assays like blood tests, which often require hours to days to yield results. The company’s innovative devices utilize multiplex electrochemical biosensor technology to simultaneously identify, analyze, and monitor multiple target biomarkers in real-time, allowing for quicker and more informed medical decisions. This technology not only facilitates decentralized testing and at-home monitoring for patients with chronic conditions but also aims to alleviate pressure on healthcare systems by providing affordable and immediate testing solutions.

Our mission is to help cities to become greener, more sustainable, more human. By installing our farms, we provide eco-systemic services to cities, improving their quality of life and creating social interactions. We want to extent our farms, and from there become the urban farming glocal leader; delivering a positive and healthy experience that will dramatically improve our clients lives.

Activ'Inside manufactures botanical ingredients and formulations to commercialize the products for well-being markets. Based in the Bordeaux area (France), Activ’Inside is an independent health food-tech company specialized in the development, production, and marketing of natural active ingredients, mainly from grape and saffron, for the health nutrition industry.

NovAliX is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry's outsourcing needs from discovery to manufacturing. With proprietary SPR technology, X-ray protein crystallography, supramolecular mass spectrometry and chemistry, NovAliX offers comprehensive integrated services for small molecule drug discovery. With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams.

OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes, France, dedicated to the development of innovative immunotherapies aimed at immune activation and regulation. The company's product portfolio includes Tedopi, an immunotherapy currently in Phase III clinical trials for lung cancer and Phase II trials for pancreatic cancer. OSE-703, a humanized monoclonal antibody, is in preclinical development for various cancers, while BI 765063 is undergoing Phase I trials for solid tumors. Additionally, FR104 is in Phase I trials for rheumatoid arthritis, and OSE-127 is in Phase I for inflammatory autoimmune diseases. OSE Immunotherapeutics has established collaborations with several prestigious organizations, including GERCOR and Memorial Sloan Kettering Cancer Center. The company was previously known as OSE Pharma SA before rebranding in May 2016.

AlgoTherapeutix SAS is a biotechnology company founded in 2018 and located in Suresnes, France, focused on developing innovative topical treatments for complex pain conditions. The company's primary product, ATX01, is designed to alleviate peripheral neuropathic pain caused by chemotherapy. By targeting the damaged nerve fibers in the skin, AlgoTherapeutix aims to provide effective pain relief while minimizing the systemic side effects associated with oral medications. The company's approach also addresses other pain syndromes, such as erythromelalgia, thereby offering medical practitioners new options to enhance patient care for those suffering from chemotherapy-induced peripheral neuropathy.

Provider of agriculture services intended to offer pesticide-free organic produce to customers. The company distributes locally grown vegetables and fruits by creating an ideal ecosystem for herbs, enabling customers to get fresh products while maintaining the biodiversity of the soil.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

SparingVision SAS is a biotechnology company based in Paris, France, focused on discovering and developing gene therapy-based treatments for blinding inherited retinal diseases. Founded in 2016, the company is working on SPVN06, a gene-independent therapy aimed at treating retinitis pigmentosa, the most common form of inherited retinal degeneration. This condition affects nearly 2 million people globally and currently lacks comprehensive treatment options for its various genetic forms. SparingVision’s efforts aim to provide innovative solutions for patients suffering from these debilitating diseases, enabling healthcare professionals to offer improved care for those at risk of blindness.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

SideROS, a biotechnology company, engages in research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells. It develops ironomycin, a chemical molecule, which disturbs iron homeostatis, involved in the maintenance of persister cancer cell, and provokes cell death by ferroptosis. The company was incorporated in 2019 and is based in Paris, France.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

Honing Biosciences SAS, a bio-therapeutics company, develops and improves cell-based therapies to treat cancer and other chronic diseases. It offers molecular CellTuneTM technology that allows to develop new classes of tunable cell therapeutics to control the dynamic delivery of proteins in patients. The company offers therapies, such as CAR-T (chimeric antigen receptor T) cells therapy to kill cancer cells and Checkpoint inhibitors, a technology allowing to select small antibodies (nanobodies) based on proprietary scaffold, which they can deliver intracellularly. Its technology regulates protein expression at the cell surface or secretion of enzymes, cytokines, antibodies, and adapting the delivery of therapeutic proteins to clinical evolutions. Honing Biosciences SAS was incorporated in 2018 and is based in Paris, France.

Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.

ABC Transfer is a biopharmaceutical company that specializes in the development of Rapid Transfer Systems (RTS) for the pharmaceutical industry. The company manufactures secure transfer systems designed specifically for sterile drug manufacturing and bioprocessing. Its innovative solutions include alpha doors, beta containers, and single-use bags, all built on patented designs. These systems enhance sterility assurance, improve operator safety, and increase overall efficiency in drug manufacturing processes. Through its focus on secure and efficient transfer methods, ABC Transfer aims to support the biopharmaceutical industry's critical need for reliable and safe drug production.

Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. As a spin-off from the ICREA and Advanced Studies and the IRB Institute for Research in Biomedicine, Ona Therapeutics focuses on the discovery and development of therapeutic biologics that target tumor metastatic-initiating cells and lipid metabolism. The company's innovative therapies aim to block pathways related to fat metabolism in animal models of cancer and inhibit the cells responsible for metastasis. This approach has the potential to prevent the development of malignant tumors and eliminate existing ones, offering new treatment options for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

Deinove SA is a France-based company active in the renewable fuels sector. It specializes in the development and commercial exploitation of processes for production of biofuels and other compounds of industrial or pharmaceutical value.

Syndivia SAS develops antibody-drug conjugates (ADC) for cancer treatment. The company provides therapeutic modalities for solid cancers based on specific targeting of the tumor microenvironment and anatomical hallmarks. It offers lead programs such as SDV1001 for pancreatic cancer and colorectal cancer and SDV1101 for breast cancer and liposarcoma. Syndivia SAS was incorporated in 2014 and is based in Illkirch-Graffenstaden, France.

Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.

Founded in 2009 and based in Lyon, France, Fab’entech is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂] aimed at treating emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab’entech provides healthcare institutions with effective therapeutic options for emergency situations. As a member of the LyonBiopôle cluster, the company contributes to advancements in medical technology and immunotherapy.

Urania Therapeutics is a biopharmaceutical company focused on developing innovative therapies for genetic diseases and cancers caused by mutations. The company specializes in the identification and creation of readthrough compounds that address premature stop codons during protein synthesis. By facilitating the production of full-length proteins, these compounds aim to treat a variety of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its unique structure-based drug design platform, Urania Therapeutics seeks to restore the production of functional proteins, thereby offering new therapeutic options for patients with these challenging conditions.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.

Naïo Technologies SAS, founded in 2011 and based in Ramonville Saint Agne, France, specializes in designing and developing electric tools for agriculture and viticulture. The company focuses on creating robots that assist in mechanical weeding, hoeing, and harvesting, thereby improving farming efficiency and reducing reliance on chemical pesticides and herbicides. Through its innovative solutions, Naïo Technologies aims to help farmers optimize their workloads, enhance profitability, and minimize environmental impact. The firm’s commitment to integrating advanced technologies in agriculture highlights its role in promoting sustainable farming practices.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.

Aelis Farma S.A.S. is a biotechnology company based in Bordeaux, France, established in 2013. The company specializes in the research and development of pregnenolone derivatives aimed at treating cannabis addiction. Aelis Farma is recognized for its innovative approach in developing signaling-specific therapeutics that target G protein-coupled receptors (GPCRs), particularly the CB1 receptor, which is widely expressed in the brain. By focusing on these receptors, Aelis Farma aims to create treatments that can selectively modulate signaling pathways, minimizing unwanted side effects commonly associated with conventional GPCR-targeting drugs. The company's work addresses critical needs in the treatment of brain diseases and addiction.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

AlgoTherapeutix SAS is a biotechnology company founded in 2018 and located in Suresnes, France, focused on developing innovative topical treatments for complex pain conditions. The company's primary product, ATX01, is designed to alleviate peripheral neuropathic pain caused by chemotherapy. By targeting the damaged nerve fibers in the skin, AlgoTherapeutix aims to provide effective pain relief while minimizing the systemic side effects associated with oral medications. The company's approach also addresses other pain syndromes, such as erythromelalgia, thereby offering medical practitioners new options to enhance patient care for those suffering from chemotherapy-induced peripheral neuropathy.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Alizé Pharma is a group of privately held biopharmaceutical companies specializing in the development of innovative biopharmaceutical drugs, proteins, and peptides, for the treatment of metabolic diseases and cancer. It is based in Ecully, near Lyon, France. Its management is made up of a team of drug development experts and a board of directors offering wide international experience. Alizé Pharma has two programs, the AZP-3601, a PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of syndromes of acute insulin resistance. The company was founded on 2015.

Microphyt, founded in 2007 and headquartered in Baillargues, France, specializes in the research, development, production, and marketing of natural algae-based products. The company focuses on microalgae and other photosynthetic microorganisms, targeting sectors such as beauty care, food, health, and energy. Its offerings include dietary supplements and products aimed at promoting weight loss and enhancing brain health. Utilizing industrial-scale cultivation techniques, Microphyt preserves the integrity of microalgae cells to produce biomass and extracts in commercial quantities. This approach enables the healthcare industry to meet the growing demand for innovative personal care and food products.

PILI Inc. researches and manufactures bio-fabricated colors by using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting colors. PILI Inc. produces renewable dyes and pigments. The company was founded in 2012 and is based in Paris, France.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

Toopi Organics SAS is a French company based in Langon that specializes in manufacturing biostimulants for agriculture derived from human urine. Founded in 2019, the company focuses on transforming and enhancing human urine with microorganisms to create natural alternatives to traditional chemical fertilizers. Its products, Arbop and Vitip, are designed to support plant growth while also promoting sustainability in farming practices. By recycling and depolluting human urine, Toopi Organics aims to provide the agricultural community with efficient and economical solutions, contributing to a more environmentally friendly approach to agriculture.

Feroscan was set up in 2014 at the initiative of its four founders bringing together scientific and business skills. Feroscan specializes in the development of first-in-class personalized cytotoxics with a unique and innovative mode of action. The pipeline of the company focuses on intractable cancers; such as ovarian, triple negative breast and NSCL cancers. Feroscan’s business strategy is to test in parallel several preclinical programs on several orphan applications up to proof of concept, IND and early clinical stages. Feroscan is based on a strong IP strategy, cutting edge science and relies on a strong academic and industrial network worldwide to develop clinical applications of its research programs.

NH TherAguix SAS, a clinical stage pharmaceutical company, develops nanomedicines for cancer, combining imaging, and radiotherapy. It offers AGuIX, a nanoparticle that is designed to improve the localization of solid tumors and the outcomes of radiation therapy by intravenous injection; allows the radiation therapy treatment for patient to determine the optimal moment to perform the irradiation; and allows to treat radioresistant cancers and to minimize the radiation therapy secondary effects by decreasing the dose to healthy tissues. The company was founded in 2015 and is based in Villeurbanne, France.

SeqOne S.A.S. is a company based in Montpellier, France, that specializes in developing genomic data analysis software for the healthcare industry. Founded in 2017, SeqOne's platform offers end-to-end management of next-generation sequencing (NGS) and bioinformatics data, providing advanced tools for analyzing complex genomic information. The software is designed to deliver medically actionable results across various areas, including oncology, hematological diseases, rare diseases, genetic screening, and hereditary conditions. By addressing the challenges associated with analyzing rich genomic data, SeqOne aims to enhance the accessibility and effectiveness of genomic medicine, thereby facilitating improved treatment options for patients. The company serves both private and public healthcare sectors, contributing to the ongoing transformation of healthcare through the integration of genomic insights.

Igyxos S.A., founded in 2017 and based in Nouzilly, France, focuses on developing innovative pharmaceuticals and medical technologies aimed at improving human fertility. The company engages in all stages of drug development, from discovering promising targets to identifying lead compounds, including small molecules and antibodies. Igyxos specializes in monoclonal antibodies that enhance the activity of gonadotropins and hormones critical for reproduction. Additionally, the company supports the transition of potential drug candidates through the pre-clinical and clinical phases of development, aiming to address the increasing global demand for effective infertility solutions for both men and women.

Deinove SA is a France-based company active in the renewable fuels sector. It specializes in the development and commercial exploitation of processes for production of biofuels and other compounds of industrial or pharmaceutical value.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Ynsect is a biotech company based in Evry, France, founded in 2011. It specializes in the production and processing of insects for use as sustainable feed in aquaculture and poultry farming. The company utilizes innovative vertical farming techniques to convert organic resources into high-quality insect-based nutrients, including proteins and lipids, which are essential for animal nutrition. In addition to feed applications, Ynsect processes insects into non-food products such as organic fertilizers and bioenergy. By automating its production processes and focusing on large-scale insect farming, Ynsect aims to provide premium organic alternatives that support the agricultural and environmental sectors. Its expertise has made it a valuable partner for agri-food professionals, laboratories, investors, and insect industry farmers.

Alkion BioInnovations specializes in the production of natural plant active ingredients for pharmaceutical applications, utilizing proprietary patented semi-industrial technologies. Established in 2017 following the acquisition of Alkion BioPharma by Evonik Industries AG, the company focuses on transforming non-GMO plants into a source of pharmacologically active compounds. Its innovative technology supports the development of disruptive nutrition, non-cosmetic oil, and agrochemical solutions. Alkion BioInnovations holds exclusive rights to these applications, catering to the pharmaceutical and agri-food markets, and has garnered interest from various sectors, including cosmetics, for its potential to revolutionize ingredient production.

Agricool SAS, founded in 2015 by Guillaume Fourdinier and Gonzague Gru, is a French company based in La Courneuve that specializes in urban farming using repurposed shipping containers. The company aims to provide local, tasty, and pesticide-free fruits and vegetables by creating controlled environments that optimize conditions for growth, including lighting, air quality, and irrigation. This innovative approach allows Agricool to achieve productivity levels 120 times greater than conventional farming methods while significantly reducing water usage by over 90%. Currently, Agricool primarily cultivates strawberries in cities like Paris and Dubai, with plans to expand its offerings to a wider variety of fruits and vegetables in the future, contributing to the urban farming movement and addressing global food supply challenges.

C4Diagnostics is a company based in Marseille, France, that specializes in the development and commercialization of in vitro diagnostic (IVD) kits. Founded in 2017, the company focuses on creating technology that enables the detection, counting, and concentration of culturable microorganisms in clinical microbiology. Its innovative approach is designed to enhance the speed and sensitivity of diagnostic tests, particularly for urinary tract infections. By providing hospitals and laboratories with advanced tools for culture-based testing and specific fluorescence, C4Diagnostics aims to improve diagnostic accuracy and efficiency in medical settings.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

Discngine provides scientific computing consulting services & solutions for Life Sciences Research. They are specialized in the integration of scientific software like BIOVIA - Accelrys Pipeline Pilot, Chemaxon, CambridgeSoft and industry standards like Oracle database or Tibco Spotfire.

PILI Inc. researches and manufactures bio-fabricated colors by using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting colors. PILI Inc. produces renewable dyes and pigments. The company was founded in 2012 and is based in Paris, France.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections. Nosopharm has set up an innovative anti-infective drug discovery platform based on the medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.